Modelling the budget impact of darunavir in the treatment of highly treatment-experienced, HIV-infected adults in France

PharmacoEconomics

Volumn 28, Issue SUPPL. 1, 2010, Pages 183-197

  Colin, Xavier ^a   Lafuma, Antoine ^a   Costagliola, Dominique ^b   Smets, Erik ^c   Mauskopf, Josephine ^d   Guillon, Pascal ^e  

^a CEMKA EVAL   (France)

^b INSERM   (France)

^c JOHNSON AND JOHNSON   (United States)

^d RTI HEALTH SOLUTIONS   (United States)

^e Janssen Cilag   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DARUNAVIR PLUS RITONAVIR; ENFUVIRTIDE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR;

ARTICLE; BUDGET; CD4 LYMPHOCYTE COUNT; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG COST; DRUG MARKETING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FRANCE; HEALTH CARE COST; HEALTH CARE SYSTEM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MODEL; PRIORITY JOURNAL;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BUDGETS; CD4 LYMPHOCYTE COUNT; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG COSTS; DRUG RESISTANCE; FRANCE; HEALTH CARE COSTS; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MODELS, STATISTICAL; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RNA, VIRAL; SULFONAMIDES; TREATMENT FAILURE; VIRAL LOAD;

EID: 78650758539     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11587520-000000000-00000     Document Type: Article

References (56)

1. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-60
2. Walensky RP, Paltiel D, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006; 194: 11-9
3. Pomerantz RJ, Horn DL. Twenty years of therapy for HIV-1 infection. Nat Med 2003; 9: 867-73
4. Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care 2006; 44: 990-7
5. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Federation National desCentres de Lutte contre le SIDA. AIDS 1997; 11: F101-5
6. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA Study: An observational study. Lancet 2003; 362: 22-9
7. Gardner LI, Klein RS, Szczech LA, et al. Rates and risk factors for condition-specific hospitalizations in HIVinfected and uninfected women. J Acquir Immune Defic Syndr 2003; 34: 320-30
8. Torti C, Casaria S, Palvarini L, et al. Modifications of health resource-use in Italy after the introduction of highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) infection. Pharmaco-economic implications in a population-based setting. Health Policy 2003; 65: 261-7
9. Gallant JE. Approach to the treatment-experienced patient. Infect Dis Clin North Am 2007; 21: 85-102
10. Department of Health and Human Services (DHHS) Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents; 2009 Dec 1 [online]. Available from URL: Http://aidsinfo.nih.gov/ContentFiles/AdultandAdoles centGL.pdf [Accessed 2009 Dec 10]
11. BHIVA Writing Committee. British HIV Association (BHIVA) draft guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIVMed 2006; 7: 487-503
12. European AIDS Clinical Society (EACS). 2007 Guidelines for the clinical management and treatment of HIV-infected adults in Europe; 2009 Nov [online]. Available from URL: Http://www.europeanaidsclinicalsociety.org/guidelines.asp [Accessed 2009 Dec 10]
13. Food and Drug Administration (FDA): Press Release: FDA approves darunavir; 2006 Jun 23 [online]. Available from URL: Www.fda.gov/NewsEvents/ Newsroom/PressAnnounce ments/2006/ucm108676.htm [Accessed 2009 Dec 10]
14. European Commission Community register of medicinal products for human use. PREZISTA; [online]. Available from URL: Http://ec.europa.eu/enterprise/ sectors/pharma ceuticals/documents/community-register/html/h380.htm [Accessed 2009 Dec 10]
15. Food and Drug Administration (FDA): Press release. FDA approves novel antiretroviral drug; 2007 Aug 6 [online]. Available from URL: Http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108960.htm [Accessed 2009 Dec 10]
16. Food and Drug Administration (FDA): Press release. FDA approves new antiretroviral drug; 2007 Oct 16 [online]. Available from URL: Http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm109008.htm [Accessed 2009 Dec 10]
17. Committee forMedicinal Products forHuman Use (CHMP) of the European Medicines Evaluation Agency (EMEA). Summary of positive opinion for raltegravir. 2007 Nov 27 [online]. Available from URL: Http://www.emea.europa.eu/pdfs/human/ press/pr/52210907en.pdf [Accessed 2009 Dec 10]
18. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: A pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369: 1169-78
19. Moeremans K, Annemans L, Löthgren M, et al. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK. PharmacoEconomics 2010; 28 Suppl. 1: 107-28
20. Mauskopf J, Brogan A, Martin S, et al. Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV- 1-infected adults in the USA. PharmacoEconomics 2010; 28 Suppl. 1: 83-105
21. Brogan A, Mauskopf J, Talbird SE, et al.US cost effectiveness of darunavir/ritonavir 600/100mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN trial. PharmacoEconomics 2010; 28 Suppl. 1: 129-46
22. Holkmann Olsen C, Gatell J, Ledergerber B, et al. Risk of AIDS and death at given HIV-RNA and CD4 cell counts, in relation to specific antiretroviral drugs in the regimen. AIDS 2005; 19: 319-30
23. Hicks C, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatmentexperienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multidrug resistant patients with Tipranavir (RESIST) studies: An analysis of combined data from two randomised openlabel trials. Lancet 2006; 368: 466-75
24. Comité Economique des Produits de Santé 2008 Article L162-17-3; [online]. Available from URL: Http://www. sante.gouv.fr/ceps [Accessed 2009 Dec 10]
25. Base de données Hospitaliére Française sur l'infection á VIH - ANRS CO4 FHDH. Inserm transfert SA, Paris, France, 2007
26. La lutte contre l'épidémie de VIH-SIDA en France - Communication du ministre de la Santé et des Solidarités relative á la lutte contre l'épidémie de VIH SIDA en France - Conseil des ministres du 28 novembre 2006; [online]. Available fromURL: Http://www.archives.premier-ministre. gouv.fr/villepin/acteurs/gouvernement/ conseils-ministres-35 /conseil-ministres-28-novembre-871/lutte-epidemie-vih- sida-57330.html [Accessed 1009 Dec 10]
27. Hill A, Moyle G. Relative antiviral efficacy of ritonavirboosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials. HIV Med 2007; 8: 259-64
28. Boehringer Ingelheim. AptivusTM (tipranavir) Prescribing Information; revised 2008 June [online]. Available from URL: Http://bidocs.boehringer- ingelheim.com/BIWebAc cess/ViewServlet.ser?docBase=renetnt&folderPath=/Pre scribing+Information/PIs/Aptivus/10003515+US+01.pdf [Accessed 2009 Dec 10]
29. Colin X, Lafuma A, Costagliola D, et al. The cost of managing HIV infection in highly treatment-experienced, HIV-infected adults in France. PharmacoEconomics 2010; 28 Suppl. 1: 59-68
30. GERS: Groupement pour l'é laboration et la Réalisation de Statistiques. Nos missions [online]. Available from URL: Http://www.gie-gers.fr/ groupement/qui-sommes-nous.php3 [Accessed 2009 Dec 10]
31. Base de données Hospitaliére Française sur l'infection á VIH - ANRSCO4 FHDH. Inserm transfert SA, Paris, France, 2006 [online]. Available from URL: Www.invs.sante.fr/beh/2007/46-47/index.htm [Accessed 2009 Dec 10]
32. Weill A, Chinaud F, Vallier N, et al. Fréquence et coǔts des trentes affections de longue durée de la région Midi- Pyréné es, année 2003. Revue Médicale de l'Assurance Maladie 2005; 4: 273-87
33. Vallier N, Weill A, Salanave B, et al. Cost of thirty long-term diseases for beneficiaries of the French general health insurance scheme in 2004. Pratique et Organisation des Soins 2006; 37: 267-83
34. Tibotec Pharmaceuticals. Clinical data of POWER clinical trial for darunavir/r. Data on file, 2007 Dec
35. Katlama C, EspositoR,Gatell JM, et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS 2007; 21: 395-402
36. Haubrich R, Berger D, Chiliade P, et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS 2007; 21: F11-18
37. Weber R, Friis-Moller N, Sabin C, et al. HIV and non- HIV-related deaths and their relationship to immunodeficiency: The D:A:D Study [abstract 595]. 12th Conference on Retroviruses and Opportunistic Infections; 2005 Feb 22-25; Boston, MA, USA
38. Hirsch HH, Kaufmann G, Sendi P, et al. Immune reconstitution in HIV-infected patients. Clin Infect Dis 2004; 38: 1159-66
39. Flori YA, le Vaillant M. Use and cost of antiretrovirals in France 1995-2000: An analysis based on the Medical Dossier on Human Immunodeficiency (release 2) database. PharmacoEconomics 2004; 22: 1061-70
40. Detournay B, Voinet C, Bez J, et al. Consommation médicale des patients infectés par le VIH suivis á l'Hǒpital Purpan (Toulouse). Journal D'Economie Médicale 2003; 21: 367-76
41. Gebo KA, Chaisson RE, Folkemer JG, et al. Costs of HIV medical care in the era of highly active antiretroviral therapy. AIDS 1999; 13: 963-9
42. U.S. Food and Drug Administration (FDA). 2008 [online]. Available from URL: Http://www.fda.gov/oashi/aids/status.html [Accessed 2009 Dec 10]
43. Ruof J, Dusek A, DeSpirito M, et al. Cost-efficacy comparison among three antiretroviral regimens in HIV-1 infected, treatment-experienced patients. Clin Drug Invest 2007; 27: 469-79
44. Schackman BR, Freedberg KA, Goldie SJ, et al. Budget impact of Medicaid Section 1115 demonstrations for early HIV treatment. Health Care Financ Rev 2005; 26: 67-80
45. Sansom SL, Anthony MN, Garland WH, et al. The costs of HIV antiretroviral therapy adherence programs and impact on health care utilization. AIDS Patient Care STDS 2008; 22: 131-8
46. Hill A, Gebo K, Hemmett L, et al. Predicting direct costs of HIV care during the first year of darunavir-based highly active antiretroviral therapy using CD4 cell counts: Evidence from POWER. PharmacoEconomics 2010; 28 Suppl. 1: 169-81
47. Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir- ritonavir at 48 weeks in treatment-experienced, HIVinfected patients in TITAN: A randomised controlled phase III trial. Lancet 2007; 370: 49-58
48. International AIDS Society - USA Panel. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society - USA Panel. JAMA 2006; 296: 827-43
49. Horne R, Clotet B, Cohen C, et al. Treatment-experienced patient perceptions of self-injectable therapy [abstract PE7.3/25]. 10th European AIDS Clinical Society Conference; 2005 Nov 11-14; Dublin, Ireland
50. Committee forMedicinal Products for HumanUse (CHMP) of the European Medicines Evaluation Agency (EMEA). Summary of positive opinion for maraviroc. 2007 [online]. Available from URL: Http://www.emea.europa.eu/humandocs/Humans/ EPAR/celsentri/celsentri.htm [Accessed 2009 Dec 10]
51. Berger DS, Northland R, Scribner A, et al. Effect of baseline factors on virological response to darunavir/r and lopinavir/r at week 48 in TITAN [abstract P7.3/27]. 11th European AIDS Conference; 2007 Oct 24-27; Madrid, Spain
52. Ortiz R, Dejesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naiv̈e HIV-1-infected patients at week 48. AIDS 2008; 22: 1389-97
53. Tibotec Pharmaceuticals. Data on file, 2007
54. Ammassari A, Trotta MP, Murri R, et al. Correlates and predictors of adherence to highly active antiretroviral therapy: Overview of published literature. J Acquir Immune Defic Syndr 2002; 31 Suppl. 3: S123-7
55. Maggiolo F, RipamontiD, AiroldiM, et al. Resistance costs and future drug options of antiretroviral therapies: Analysis of the role of NRTIs, NNRTIs, and PIs in a large clinical cohort. HIV Clin Trials 2007; 8: 9-18
56. Negredo E, Bonjoch A, Clotet B. Benefits and concerns of simplification strategies in HIV-infected patients. J Antimicrob Chemother 2006; 58: 235-42